A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Published:2014-12-23 Issue:1 Volume:90 Page:42-49
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Orlowski Robert Z.¹,Gercheva Liana²,Williams Cathy³,Sutherland Heather⁴,Robak Tadeusz⁵,Masszi Tamás⁶,Goranova-Marinova Vesselina⁷,Dimopoulos Meletios A.⁸,Cavenagh James D.⁹,Špička Ivan¹⁰,Maiolino Angelo¹¹,Suvorov Alexander¹²,Bladé Joan¹³,Samoylova Olga¹⁴,Puchalski Thomas A.¹⁵,Reddy Manjula¹⁵,Bandekar Rajesh¹⁵,van de Velde Helgi¹⁶,Xie Hong¹⁵,Rossi Jean-Franςois¹⁷

Affiliation:

1. Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston Texas

2. University Hospital for Active Treatment “St. Marina,”; Varna Bulgaria

3. Nottingham University Hospitals NHS Trust; Nottingham United Kingdom

4. Vancouver General Hospital; Vancouver Canada

5. Medical University of Łódź and Copernicus Memorial Hospital; Łódź Poland

6. St. Istvan and St. Laszlo Hospital of Budapest and Semmelweis University; Budapest Hungary

7. University Multiprofile Hospital for Active Treatment “St. George,”; Plovdiv Bulgaria

8. National and Kapodistrian University of Athens; Athens Greece

9. St. Bartholomew's and the London Hospital; London United Kingdom

10. Charles University in Prague; Prague Czech Republic

11. Universidade Federal do Rio de Janeiro; Rio de Janeiro Brazil